2-((3-bromoprop-2-yn-1-yl)(t-butoxycarbonyl)amino)acetic acid | 1567373-43-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-((3-bromoprop-2-yn-1-yl)(t-butoxycarbonyl)amino)acetic acid
• 英文别名: N-(3-bromoprop-2-yn-1-yl)-N-(tert-butoxycarbonyl)glycine；2-[3-Bromoprop-2-ynyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid；2-[3-bromoprop-2-ynyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid
• CAS: 1567373-43-6
• 化学式: C₁₀H₁₄BrNO₄
• 分子量: 292.129
• InChiKey: FIQHROOXVDNWDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-((3-bromoprop-2-yn-1-yl)(t-butoxycarbonyl)amino)acetic acid 在 N-甲基吗啉 、 四氯化碳 、 palladium diacetate 、 三乙酰氧基硼氢化钠 、 sodium carbonate 、 三乙胺 、 三(邻甲基苯基)磷 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  新型四氢吡咯并[3,4- c ]吡唑类化合物作为N型钙通道抑制剂的发现与合成孔径雷达

  摘要：

  研究了一系列新的取代四氢吡咯并[3,4- c ]吡唑类化合物作为慢性疼痛目标N型钙通道（Ca v 2.2通道）的阻滞剂。

  DOI：

  10.1016/j.bmcl.2014.03.062
• 作为产物：
  描述：

  2-((tert-butoxycarbonyl)(prop-2-yn-1-yl)-amino)acetic acid 在 溴 、 potassium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 1.25h， 以47%的产率得到2-((3-bromoprop-2-yn-1-yl)(t-butoxycarbonyl)amino)acetic acid
  参考文献：
  名称：

  分子内腈亚胺环加成反应合成取代的2,4,5,6-四氢环戊[ c ]吡唑和2,4,5,6-四氢吡咯并[3,4- c ]吡唑

  摘要：

  取代的2,4,5,6-四氢环戊[ c ]吡唑和2,4,5,6-四氢吡咯并[3,4- c ]吡唑是通过亚硝胺的3 + 2分子内偶极环加成反应而合成的。通过使用炔基溴化物作为亲双性体，这种环化作用已扩展为更通用的3-溴衍生物。

  DOI：

  10.1016/j.tetlet.2014.02.068

文献信息

• Synthesis of substituted 2,4,5,6-tetrahydrocyclopenta[c]pyrazoles and 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles by intramolecular nitrilimine cycloaddition
  作者：Michael P. Winters、Christopher A. Teleha、Zhihua Sui

  DOI：10.1016/j.tetlet.2014.02.068

  日期：2014.3

  Both substituted 2,4,5,6-tetrahydrocyclopenta[c]pyrazoles and 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles have been synthesized by the 3+2 intramolecular dipolar cycloaddition of nitrilimines to alkynes. This cyclization has been extended to more versatile 3-bromo derivatives by the use of alkynylbromides as dipolarophiles.

  取代的2,4,5,6-四氢环戊[ c ]吡唑和2,4,5,6-四氢吡咯并[3,4- c ]吡唑是通过亚硝胺的3 + 2分子内偶极环加成反应而合成的。通过使用炔基溴化物作为亲双性体，这种环化作用已扩展为更通用的3-溴衍生物。
• [EN] PYRROLOPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS<br/>[FR] PYRROLOPYRAZOLES COMME BLOQUEURS DE CANAL CALCIQUE DE TYPE N
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014028805A1

  公开（公告）日：2014-02-20

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: Formula. (I) wherein R1, R2 R3, Q, and G are defined herein.

  揭示了用于治疗各种疾病、综合症、症状和障碍的化合物、组合物和方法，包括疼痛。这些化合物由以下的化学式I表示：化学式（I），其中R1、R2、R3、Q和G在此处被定义。
• PYRROLOPYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140051688A1

  公开（公告）日：2014-02-20

  Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: wherein R 1 , R 2 , R 3 , Q, and G are defined herein.
• US8846949B2
  申请人：——

  公开号：US8846949B2

  公开（公告）日：2014-09-30
• Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels
  作者：Krystian A. Kozek、Yu Du、Swagat Sharma、Francis J. Prael、Brittany D. Spitznagel、Sujay V. Kharade、Jerod S. Denton、Corey R. Hopkins、C. David Weaver

  DOI：10.1021/acschemneuro.8b00287

  日期：2019.1.16

  G protein-gated, inwardly rectifying, potassium (GIRK) channels are important regulators of cellular excitability throughout the body. GIRK channels are heterotetrameric and homotetrameric combinations of the K(ir)3.1-4 (GIRK1-4) subunits. Different subunit combinations are expressed throughout the central nervous system (CNS) and the periphery, and most of these combinations contain a GIRK1 subunit. For example, the predominance of GIRK channels in the CNS are composed of GIRK1 and GIRK2 subunits, while the GIRK channels in cardiac atrial myocytes are made up mostly of GIRK1 and GIRK4 subunits. Although the vast majority of GIRK channels contain a GIRK1 subunit, discrete populations of cells that express non-GIRK1-containing GIRK (non-GIRK1/X) channels do exist. For instance, dopaminergic neurons in the ventral tegmental area of the brain, associated with addiction and reward, do not express the GIRK1 subunit. Targeting these non-GIRK1/X channels with subunit-selective pharmacological probes could lead to important insights into how GIRK channels are involved in reward and addiction. Such insights may, in turn, reveal therapeutic opportunities for the treatment or prevention of addiction. Previously, our laboratory discovered small molecules that can specifically modulate the activity of GIRK1-containing GIRK channels. However, efforts to generate compounds active on non-GIRK1/X channels from these scaffolds have been unsuccessful. Recently, ivermectin was shown to modulate non-GIRK1/X channels, and historically, ivermectin is known to modulate a wide variety of neuronal channels and receptors. Further, ivermectin is a complex natural product, which makes it a challenging starting point for development of more selective, effective, and potent compounds. Thus, while ivermectin provides proof-of-concept as a non-GIRK1/X channel activator, it is of limited utility. Therefore, we sought to discover a synthetic small molecule that would serve as a starting point for the development of non-GIRK1/X channel modulators. To accomplish this, we used a high-throughput thallium flux assay to screen a 100 000-compound library in search of activators of homomeric GIRK2 channels. Using this approach, we discovered VU0529331, the first synthetic small molecule reported to activate non-GIRK1/X channels, to our knowledge. This discovery represents the first step toward developing potent and selective non-GIRK1/X channel probes. Such molecules will help elucidate the role of GIRK channels in addiction, potentially establishing a foundation for future development of therapies utilizing targeted GIRK channel modulation.